ACTG 362: AZITHROMYCIN PROPHYLAXIS FOR PRIMARY PREVENTION OF MAC IN AIDS

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 这是一项随机安慰剂对照研究，旨在确定阿奇霉素在抗逆转录病毒治疗后CD 4细胞增加（从100个细胞/mm 3）的受试者中用于一级预防鸟分枝杆菌复合体（MAC）和其他感染的疗效< 50 to >。 受试者可能既往未诊断为MAC，将接受1200 mg阿奇霉素，每周一次。主要终点是比较MAC发生的时间。有许多次要目的和几个子研究评价阿奇霉素对HIV+患者常见的其他细菌感染的影响。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a randomized placebo-controlled study to determine the efficacy of Azithromycin for primary prevention of Mycobacterium Avium Complex (MAC) and other infections in subjects who have acheived an increase in CD4 cells (from < 50 to >100 cells/mm3) on antiretroviral therapy. Subjects may not have had a prior diagnosis of MAC and will receive 1200 mg of Azithromycin once a week. The primary endpoint is to compare the time to development of MAC. There are numerous secondary objectives and several substudies evaluating azithromycin's effect on other bacterial infections common in the HIV+ patient.